Stocktoria
VivoSim Labs, INC. VIVS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2013-08-02
VivoSim Labs, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -8761.1% | -13840.4% | -4792.2% | -765.3% | — |
| Net margin | -1727.8% | -13459.6% | -4664.6% | -763.2% | — |
| FCF margin | -6579.2% | -13481.7% | -3460.5% | -590.8% | — |
| Return on assets | -17.0% | -231.1% | -85.0% | -34.4% | -42.2% |
| Return on equity | -23.7% | -407.4% | -112.6% | -37.9% | -42.9% |
| Current ratio | 3.25 | 2.12 | 4.64 | 21.35 | 53.26 |
| Revenue growth | 32.1% | -70.5% | -75.3% | — | -100.0% |
Source: SEC EDGAR filings · CIK 0001497253 · as of 2025-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.